Haloperidol (Haldol): the high-potency typical antipsychotic

Haloperidol — sold under the brand name Haldol and dozens of generics — has been used in psychiatric care since 1958. It was discovered in Belgium by Paul Janssen, and within a decade it had become one of the most prescribed antipsychotics in the world. More than 60 years later, it is still on the WHO Model List of Essential Medicines and remains a first-line option in emergency settings, lower-resource health systems, and long-acting depot maintenance.

What haloperidol is

Haloperidol belongs to the chemical class called butyrophenones. Pharmacologically it is a high-potency typical antipsychotic, which means small doses (in milligrams) produce strong dopamine D2 receptor blockade. Unlike many sedating antipsychotics, it has limited activity at histamine, muscarinic, and adrenergic receptors — which is why it tends to be less sedating and to cause less weight gain than chlorpromazine or olanzapine.

How it works

Haloperidol blocks dopamine D2 receptors throughout the brain. Blockade in the mesolimbic pathway is thought to reduce positive symptoms of psychosis. Unfortunately, the same blockade in the nigrostriatal pathway is what produces the movement side effects (extrapyramidal symptoms, or EPS) that haloperidol is most known for. Its tight, selective binding to D2 receptors is both its strength and its main drawback.

What it treats

Haloperidol is FDA-approved for:

• Schizophrenia — both acute episodes and long-term maintenance
• Tourette's syndrome — to reduce severe tics
• Severe behavioural problems in children with combative explosive behaviour (a narrow indication used cautiously)

It is also widely used off-label for acute agitation in emergency rooms (often in combination with lorazepam), delirium in hospitalised adults, and intractable nausea and vomiting in palliative care.

Forms and dosing

Haloperidol is available in several forms:

• Oral tablets and oral concentrate
• Intramuscular injection (haloperidol lactate) for acute use
• Long-acting injection (haloperidol decanoate) for monthly maintenance

Typical daily oral doses for chronic schizophrenia tend to be modest — often in the single-digit milligram range — though acute or treatment-resistant cases sometimes use more. Decisions about dose are highly individual and belong with your prescriber. The decanoate form releases haloperidol slowly over about 4 weeks and is dosed roughly every 28 days.

How effective it is

Haloperidol is consistently among the most effective antipsychotics for positive symptoms in network meta-analyses, including the influential Leucht 2013 paper in The Lancet. In the landmark CATIE trial, perphenazine (a similar typical) performed comparably to most second-generation drugs. Translation: high-potency typicals like haloperidol still hold their own in head-to-head efficacy, even though newer drugs are usually preferred for their gentler movement-side-effect profile.

Side effects to know about

Extrapyramidal symptoms (EPS)

This is the headline issue with haloperidol. EPS includes:

• Acute dystonia — sudden, painful muscle spasms (often of the neck, jaw, or eyes), usually within hours to days of starting or increasing the dose
• Parkinsonism — tremor, rigidity, slowed movement, a shuffling gait, and reduced facial expression
• Akathisia — an internal restlessness that makes it hard to sit still; often distressing and easily missed
• Tardive dyskinesia (TD) — late-onset involuntary movements, especially of the face and tongue, that can be permanent

See our deeper guides on extrapyramidal symptoms and tardive dyskinesia.

Other effects

• QT-interval prolongation on the ECG, particularly with IV use
• Hyperprolactinaemia (elevated prolactin), which can cause menstrual changes, breast tenderness, or sexual dysfunction
• Sedation (mild to moderate, less than chlorpromazine)
• Anticholinergic effects (dry mouth, constipation) are usually limited
• Weight gain and metabolic effects are typically less than with most second-generation drugs

Who haloperidol fits well

• Patients with prominent positive symptoms who tolerate movement-side-effect risk well
• Patients who have responded to it before
• Settings where cost or supply of newer antipsychotics is a barrier
• Acute agitation in the emergency room (short-term use)
• Patients moving to a long-acting depot for adherence support

Who might want to consider alternatives

• People with strong negative or cognitive symptoms (where atypicals may help slightly more)
• People with a history of severe EPS or tardive dyskinesia
• Older adults with dementia — the FDA has a boxed warning against antipsychotic use for dementia-related psychosis because of increased mortality
• People with significant cardiac conduction problems

Practical questions worth asking your prescriber

• What is the lowest effective dose for me?
• Should I take a prophylactic anticholinergic (like benztropine) for the first weeks?
• How often will we screen for tardive dyskinesia (e.g., the AIMS scale)?
• If oral haloperidol works, would the decanoate depot be a good fit?

The bigger picture

It is easy to dismiss the older antipsychotics as obsolete, but haloperidol remains genuinely useful — particularly when used at the lowest effective dose, with active EPS monitoring, and with informed conversations between patient and prescriber. For the right person, it can deliver decades of stability at a fraction of the cost of newer drugs.

This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.